Novartis

Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials Bexsero, already licensed in Europe, Australia and Canada, is the only broad coverage vaccine to help protect against MenB disease MenB is … Read the full press release →

In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase … Read the full press release →

ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Glivec[1] Data demonstrated higher rates of early and deeper molecular response in newly diagnosed patients, including MR4.5, and a reduced … Read the full press release →

Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria. The Novartis Foundation for Sustainable Development (NFSD) launches a new strategy to help eliminate leprosy. For over 15 years, the annual symposium of … Read the full press release →

Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the potential to be the first treatment for sIBM patients BYM338 is the third Novartis investigational treatment this year to receive … Read the full press release →

The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60 selected students from leading international universities attend to explore science and innovation at Novartis headquarters in Basel, Switzerland Novartis CEO … Read the full press release →

Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading … Read the full press release →

Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of … Read the full press release →

Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 … Read the full press release →

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase III trials across five molecules Global program underscores Sandoz’s leadership in biosimilars Holzkirchen, Germany, 1-7-2013 — /europawire.eu/ — Sandoz, the global … Read the full press release →

Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four … Read the full press release →

Revenue for the first quarter of 2013 amounted to DKK 19.5 billion – driven by an organic growth of 2.7% Operating margin was 4.4% compared with 4.5% for the same period in 2012 Net profit was DKK 71 million compared … Read the full press release →

2-4-2013 — /europawire.eu/ — The shareholders of AarhusKarlshamn AB (publ) are hereby invited to attend the Annual General Meeting to be held on Friday 3 May 2013 at 2.00 p.m. at Europaporten Kongresscenter, Stadiongatan 25 in Malmö, Sweden. The registration for the … Read the full press release →

Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon Paris and Strasbourg, France – 25-3-2013 — /europawire.eu/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (NYSE-Euronext: TNG) announced today a collaboration agreement for the creation of a new … Read the full press release →

Princeton, New Jersey, 5-3-2013 — /europawire.eu/ — Sandoz today announced the US launch of an authorized generic version of Eagle Pharmaceuticals’ ready-to-use argatroban injection 50 mg/50mL, aqueous solution (1 mg/mL). Argatroban injection is indicated for prophylaxis or treatment of thrombosis in adult … Read the full press release →

BT Group plc (BT.L) today announced its results for the third quarter and nine months to 31 December 2012.  7-2-2013 — /europawire.eu/ — Ian Livingston, Chief Executive, commenting on the results, said: “Our fibre plans are helping to make the UK … Read the full press release →

24-1-2013 — /europawire.eu/ — The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ruvise (imatinib mesilate), 100 and 400 mg film-coated tablets. It was … Read the full press release →

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year net sales were USD 56.7 billion (-3%, … Read the full press release →

Pivotal data showed Jetrea significantly resolved vitreomacular traction (VMT) and macular hole compared to placebo at day 28 (p<0.001)[1] Current standard of care for VMT is surgery or “watchful waiting” associated with further visual impairment that can lead to central … Read the full press release →

Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life to track the use and stock of leprosy medicines, and … Read the full press release →